• Equasens: RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING OF 27 JUNE 2024

    Source: Nasdaq GlobeNewswire / 05 Jul 2024 12:00:00   America/New_York

            

    Villers-lès-Nancy, 5 July 2024 - 6:00 p.m. (CET)

    PRESS RELEASE

    RESULTS OF THE VOTES ON THE RESOLUTIONS SUBMITTED
    TO THE ORDINARY ANNUAL SHAREHOLDERS' MEETING
    OF 27 JUNE 2024

    Number of shares comprising the share capital: 15,174,125

    Number of shares with voting rights: 15,031,080

    Number of shares with voting rights possessed by shareholders presents or represented or having voted by mail: 13,070,268

    That means a quorum of 86.95% of the 15,031,080 shares with voting rights: the Ordinary Annual General Meeting was able to deliberate.

    The Ordinary Annual General Meeting was held on Thursday, 27 June 2024 at 5:30 p.m. at the Company’s headquarters and approved the separate parent company and consolidated financial statements for the 2023 financial year. The results of the votes on the resolutions proposed at this meeting by the Board of Directors were as follows:

    Resolutions  

    Results of the votes

     
    • RESOLUTION ONE
    Approval of the annual financial statements    		Resolution adopted by:
    • 13,068,136 votes in favour
    • 0 vote against
    • 2,132 abstentions
    • RESOLUTION TWO
    Discharge of directors and discharge of the Statutory Auditors for the performance of their engagement    		Resolution adopted by:
    • 12,777,518 votes in favour
    • 290,512 votes against
    • 2,238 abstentions
    • RESOLUTION THREE
      Approval of the consolidated financial statements
    		Resolution adopted by:
    • 13,068,136 votes in favour
    • 0 vote against
    • 2,132 abstentions
    • RESOLUTION FOUR
    Appropriation of earnings, setting the dividend    		Resolution adopted by:
    • 13,070,236 votes in favour
    • 0 vote against
    • 32 abstentions
    • RESOLUTION FIVE
    Agreements and commitments governed by Articles L. 225-38 of the French Commercial Code    		Resolution adopted by (*):
    • 13,023,724 votes in favour
    • 46,492 votes against
    • 32 abstentions
    • RESOLUTION SIX
    Renewal of Ms. Sophie MAYEUX's term of office as Director    		Resolution adopted by:
    • 10,650,758 votes in favour
    • 2,419,478 votes against
    • 32 abstentions
    • RESOLUTION SEVEN
    Appointment of BM&A as Sustainability Auditor    		Resolution adopted by:
    • 13,070,236 votes in favour
    • 0 vote against
    • 32 abstentions
    • RESOLUTION EIGHT
    Approval of the information on the compensation of corporate officers paid in or granted for fiscal 2023 and mentioned in Article L. 22-10-9 of the French Commercial Code    		Resolution adopted by:
    • 12,189,192 votes in favour
    • 881,044 votes against
    • 32 abstentions
    • RESOLUTION NINE
    Approval of the components of compensation paid in 2023 to Mr. Thierry CHAPUSOT, Chairman of the Board of Directors    		Resolution adopted by:
    • 13,006,839 votes in favour
    • 63,397 votes against
    • 32 abstentions
    • RESOLUTION TEN
    Approval of the components of compensation paid in 2023 to Mr. Dominique PAUTRAT, Chief Executive Officer until 22/04/2022    		Resolution adopted by:
    • 13,070,236 votes in favour
    • 0 vote against
    • 32 abstentions
    • RESOLUTION ELEVEN
    Approval of the components of compensation paid in 2023 to Mr. Denis SUPPLISSON, Chief Executive Officer    		Resolution adopted by:
    • 10,519,109 votes in favour
    • 2,551,127 votes against
    • 32 abstentions
    • RESOLUTION TWELVE
    Approval of the components of compensation paid in 2023 to Mr. Grégoire DE ROTALIER, Deputy CEO    		Resolution adopted by:
    • 10,468,599 votes in favour
    • 2,601,637 votes against
    • 32 abstentions
    • RESOLUTION THIRTEEN
    Approval of the compensation policy for Mr. Thierry CHAPUSOT, Chairman of the Board of Directors, for 2024    		Resolution adopted by:
    • 13,006,839 votes in favour
    • 63,397 votes against
    • 32 abstentions
    • RESOLUTION FOURTEEN
    Approval of the compensation policy for Mr. Denis SUPPLISSON, Chief Executive Officer, for 2024    		Resolution adopted by:
    • 10,473,009 votes in favour
    • 2,356,603 votes against
    • 240,656 abstentions
    • RESOLUTION FIFTEEN
    Approval of the compensation policy for Mr. Grégoire de ROTALIER, Deputy Chief Executive Officer, for 2024    		Resolution adopted by:
    • 10,472,921 votes in favour
    • 2,356,691 votes against
    • 240,656 abstentions
    • RESOLUTION SIXTEEN
    Approval of the compensation policy for Mr. Damien VALICON, Deputy CEO (non-Board member), as from 01/04/2024    		Resolution adopted by:
    • 10,462,222 votes in favour
    • 2,367,390 votes against
    • 240,656 abstentions
    • RESOLUTION SEVENTEEN
    Approval of the compensation policy for Directors    		Resolution adopted by:
    • 12,985,338 votes in favour
    • 63,397 votes against
    • 21,533 abstentions
    • RESOLUTION EIGHTEEN
    Setting total annual compensation for Directors for 2024    		Resolution adopted by:
    • 12,985,338 votes in favour
    • 63,397 votes against
    • 21,533 abstentions
    • RESOLUTION NINETEEN
    Authorisation by the Company to repurchase its own shares    		Resolution adopted by:
    • 10,931,253 votes in favour
    • 2,139,015 votes against
    • 0 abstention
    • RESOLUTION TWENTY
    Powers for formalities    		Resolution adopted by:
    • 13,070,236 votes in favour
    • 0 vote against
    • 32 abstentions

    (*) After deduction of excluded voting rights

    Financial Calendar:

    • Publication of H1 2024 Revenue: 2 August 2024 (after French market closure).

    About Group Equasens

    With more than 1,300 employees, Equasens Group is today a key player in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centres) in both primary and secondary care sectors.

    With operations in France, Germany, Great Britain, Belgium, Ireland, Italy, and Luxembourg, Equasens Group today brings together healthcare professionals within a unique ecosystem in France and Europe benefiting people by making available the very best of technology.

    Listed on Euronext Paris™ - Compartment B
    Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable
    Included in the Euronext Tech Leaders segment and the European Rising Tech label

    Eligible for the Deferred Settlement Service (“Service à Règlement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME)
    ISIN: FR 0012882389 – Ticker Code: EQS

    Get all the news about the Equasens Group www.equasens.com and on LinkedIn

    CONTACTS

    Analyst and Investor Relations:
    Chief Administrative and Financial Officer: Frédérique SCHMIDT
    Tel. +33 (0)3 83 15 90 67 - frederique.schmidt@equasens.com

    Media Relations:
    FIN’EXTENSO - Isabelle APRILE
    Tel. +33 (0)6 17 38 61 78 – i.aprile@finextenso.fr

    Attachment


Share on,